| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
40,010,000 |
| Market
Cap: |
925.03(M) |
| Last
Volume: |
1,008,943 |
Avg
Vol: |
1,006,166 |
| 52
Week Range: |
$12.64 - $30.11 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Cassava Sciences is a clinical-stage biotechnology company. Co. has combined technology with insights in neurobiology to develop solutions for Alzheimer's disease and other neurodegenerative diseases. Co. has two biopharmaceutical assets under development: its primary therapeutic product candidate, called simufilam, is a treatment for Alzheimer's disease; and its primary investigational diagnostic product candidate, called SavaDx, is a way to detect the existence of Alzheimer's disease from a small sample of blood.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
48,477 |
278,477 |
| Total Buy Value |
$0 |
$0 |
$831,428 |
$6,164,449 |
| Total People Bought |
0 |
0 |
2 |
4 |
| Total Buy Transactions |
0 |
0 |
3 |
9 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Barbier Remi |
President and CEO |
• • – |
2022-06-06 |
4 |
D |
$27.93 |
$1,528,330 |
D/D |
(54,720) |
767,717 |
|
- |
|
| Barbier Remi |
President and CEO |
• • – |
2022-06-06 |
4 |
OE |
$23.38 |
$1,528,304 |
D/D |
65,368 |
822,437 |
|
- |
|
| Friedmann Nadav |
Chief Medical Officer |
• • – |
2022-05-27 |
4 |
D |
$26.66 |
$655,010 |
D/D |
(24,569) |
70,534 |
|
- |
|
| Friedmann Nadav |
Chief Medical Officer |
• • – |
2022-05-27 |
4 |
OE |
$23.38 |
$654,967 |
D/D |
28,014 |
95,103 |
|
- |
|
| Barbier Remi |
President and CEO |
• • – |
2022-04-25 |
4 |
OE |
$0.95 |
$118,703 |
I/I |
49,460 |
376,112 |
|
- |
|
| Gussin Robert Z |
Director |
– • – |
2022-03-29 |
4 |
D |
$39.98 |
$160,880 |
D/D |
(4,024) |
8,410 |
|
- |
|
| Gussin Robert Z |
Director |
– • – |
2022-03-29 |
4 |
OE |
$20.30 |
$160,856 |
D/D |
7,470 |
12,434 |
|
- |
|
| Robertson Sanford |
Director |
– • – |
2022-03-25 |
4 |
OE |
$20.30 |
$94,801 |
D/D |
4,670 |
924,765 |
|
- |
|
| Gussin Robert Z |
Director |
– • – |
2021-09-15 |
4 |
D |
$43.92 |
$76,684 |
D/D |
(1,746) |
4,964 |
|
- |
|
| Gussin Robert Z |
Director |
– • – |
2021-09-15 |
4 |
OE |
$27.37 |
$76,663 |
D/D |
2,801 |
6,710 |
|
- |
|
| Barry Richard |
Director |
– • – |
2021-06-11 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
150,000 |
|
-38% |
|
| Barbier Remi |
President and CEO |
• • – |
2021-05-27 |
4 |
D |
$55.60 |
$3,000,454 |
D/D |
(53,965) |
1,080,920 |
|
- |
|
| Barbier Remi |
President and CEO |
• • – |
2021-05-27 |
4 |
OE |
$53.55 |
$3,000,407 |
D/D |
56,030 |
1,134,885 |
|
- |
|
| Robertson Sanford |
Director |
– • – |
2021-03-30 |
4 |
OE |
$27.37 |
$305,521 |
D/D |
7,472 |
920,095 |
|
- |
|
| Friedmann Nadav |
Chief Medical Officer |
• • – |
2021-03-17 |
4 |
D |
$62.52 |
$1,500,230 |
D/D |
(23,996) |
68,429 |
|
- |
|
| Friedmann Nadav |
Chief Medical Officer |
• • – |
2021-03-17 |
4 |
OE |
$53.55 |
$1,500,203 |
D/D |
28,015 |
92,428 |
|
- |
|
| O Donnell Michael J |
Director |
– • – |
2021-03-16 |
4 |
D |
$52.16 |
$228,826 |
D/D |
(4,387) |
4,870 |
|
- |
|
| O Donnell Michael J |
Director |
– • – |
2021-03-16 |
4 |
OE |
$49.00 |
$228,781 |
D/D |
4,669 |
9,257 |
|
- |
|
| Barbier Remi |
President and CEO |
• • – |
2020-09-24 |
4 |
B |
$9.59 |
$95,900 |
D/D |
10,000 |
1,078,855 |
2.81 |
361% |
|
| Robertson Sanford |
Director |
– • – |
2020-09-18 |
4 |
B |
$8.92 |
$323,627 |
D/D |
36,281 |
912,623 |
2.39 |
128% |
|
| Robertson Sanford |
Director |
– • – |
2020-09-17 |
4 |
B |
$6.98 |
$1,491,759 |
D/D |
213,719 |
876,342 |
2.39 |
180% |
|
| Schoen Eric |
Chief Financial Officer |
• – – |
2020-09-17 |
4 |
B |
$7.04 |
$14,080 |
I/I |
2,000 |
27,300 |
1.99 |
180% |
|
| Schoen Eric |
Chief Financial Officer |
• – – |
2020-09-17 |
4 |
B |
$7.03 |
$70,300 |
D/D |
10,000 |
25,300 |
2.74 |
180% |
|
| Barbier Remi |
President and CEO |
• • – |
2019-12-31 |
4 |
B |
$5.53 |
$553,000 |
D/D |
100,000 |
1,068,855 |
2.81 |
58% |
|
| Barbier Remi |
President and CEO |
• • – |
2019-12-26 |
4 |
B |
$4.15 |
$41,500 |
I/I |
10,000 |
968,855 |
2.66 |
- |
|
83 Records found
|
|
Page 2 of 4 |
|
|
1.56 (7.24%) 
